$PTIX

ARMEN GARO H purchased $945 of PTIX

ARMEN GARO H (EXEC. CHAIR & PRINCIPAL OFF) purchased 2,700 shares of Protagenic Therapeutics, Inc.\new (PTIX) at $0.35 on 2026-08-19.

Original reporting
SEC EDGAR · ARMEN GARO H
Published Aug 20, 2026, 1:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PTIX
Neutral
high confidence
Mentioned
$PTIX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTIXNeutralLow
01

Why it matters

The disclosed purchase adds a minor data point to PTIX's insider activity profile.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical data releases could make the insider's confidence more meaningful.

Relevance 4/10Novelty 2/10Timing: filed today

Background

Form 4 filings disclose insider transactions; PTIX is a clinical-stage biotech listed on Nasdaq.

Company-level read

Ticker impact

$PTIXNeutralHigh confidence
Context

Exec Chair Armen Garo H purchased 2,700 shares of PTIX at $0.35 each, total $945, filing a Form 4 on 2026-08-20.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

The purchase is under $1M and represents a tiny fraction of float, unlikely to move the stock materially.

Market effects

None significant; biotech sector not materially affected by a micro insider trade.

No regional impact.

Negligible.

Counterpoint

The insider purchase could be a subtle signal of upcoming positive news, but size is too small to be reliable.

Key entities

  • Armen Garo H

    Executive Chair & Principal Officer of PTIX.

  • Protagenic Therapeutics, Inc.

    Biotech firm developing therapies for rare diseases.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PTIXMedAI 8/10

Protagenic Therapeutics, Inc.: Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder

Protagenic Therapeutics (PTIX) received FDA feedback supporting its planned Phase 1 program for PT00114, a treatment for generalized anxiety disorder. The FDA raised no objections to the program design, dose-escalation approach, or CMC and nonclinical packages. The company plans to submit the IND before the end of 2026 and target first patient dosing in the first half of 2027. PT00114 has shown promising results in preclinical and early-phase studies.

$PTIXMed

Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY

^ Original-Research: Pentixapharm Holding AG - from NuWays AG 31.07.2026 / 09:00 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.